Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Immunocore in a research report issued on Wednesday, February 26th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings per share of ($0.39) for the quarter. The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore's Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.41) EPS and FY2026 earnings at ($2.38) EPS.
A number of other brokerages have also weighed in on IMCR. Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a report on Friday. Mizuho downgraded shares of Immunocore from an "outperform" rating to a "neutral" rating and lowered their price objective for the stock from $72.00 to $38.00 in a report on Monday, November 11th. Finally, Needham & Company LLC restated a "buy" rating and set a $71.00 price objective on shares of Immunocore in a report on Thursday. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, Immunocore currently has an average rating of "Moderate Buy" and an average price target of $65.64.
View Our Latest Report on Immunocore
Immunocore Stock Down 0.7 %
NASDAQ:IMCR traded down $0.21 on Thursday, hitting $29.37. The stock had a trading volume of 181,954 shares, compared to its average volume of 229,183. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. Immunocore has a 52 week low of $27.69 and a 52 week high of $72.05. The business's fifty day moving average is $30.08 and its 200 day moving average is $31.85. The company has a market cap of $1.47 billion, a PE ratio of -30.92 and a beta of 0.77.
Institutional Trading of Immunocore
A number of institutional investors and hedge funds have recently modified their holdings of IMCR. Primecap Management Co. CA increased its position in shares of Immunocore by 26.7% during the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company's stock valued at $76,954,000 after purchasing an additional 520,950 shares during the last quarter. State Street Corp increased its holdings in Immunocore by 63.9% during the third quarter. State Street Corp now owns 76,671 shares of the company's stock worth $2,387,000 after buying an additional 29,897 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after purchasing an additional 109,206 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in shares of Immunocore by 125.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company's stock worth $1,463,000 after purchasing an additional 27,598 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Immunocore by 7,437.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company's stock worth $2,872,000 after purchasing an additional 91,033 shares during the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.
Immunocore Company Profile
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
See Also
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
